• Ran Wang

    Founding Partner and CEO

    • Over 25 years of experience in investment banking
    • Previously worked at JP Morgan Chase and Goldman Sachs
    • BS and MBA from Harvard University
                                        
    Cancel
    Mr. Wang has 25 years of investment banking experience and is widely recognized as one of the most influential figures and pioneers in China's investment banking industry. He founded CEC Capital Group (formerly known as China eCapital Group) in 2000 and is now chairman and CEO of the firm. Under his leadership, CEC Capital, which has closed over 500 transactions with total deal value exceeding RMB500 billion, has emerged as a leading private investment bank and asset management firm with a core focus on the TMT, consumer and healthcare sectors. 
    
    Mr. Wang started his investment banking career at Goldman Sachs in 1994. Prior to founding CEC Capital, he had spent the previous three years with the Global M&A Group of JP Morgan, where he was responsible for developing and executing a number of large M&A transactions in the Asia-Pacific region. Mr. Wang has a bachelor degree in economics from Harvard College and an MBA from Harvard Business School. He has published extensively in leading Chinese financial press.
  • Irene Hong

    Founding Partner

    • Over 20 years of experience in investment banking and the healthcare industry
    • Previously worked at Merck and Accenture
    • BS in Mechanical Engineering and MBA from U.C. Berkeley
                                        
    Cancel
    Ms. Hong is a founding partner for CEC Capital Group, and leads the healthcare industry group.  Under her guidance, CEC Capital has emerged as a leader in the healthcare banking sector with the largest specialized team covering pharma/biotech, medtech, services, and digital healthcare.  Notable clients include Arrail Dental, Berry Genomics, China Medical Diagnostics Corporation, Righton Bio, Sino-Kor Hospital, and Reach Surgical.  CEC Capital also has a strong cross-border practice, having worked in the past with several multinational companies including Zimmer, Charles River, and Teva.  With an increasing interest in China outbound investment, CEC Capital has opened an office in the US and Ms. Hong will be leading this cross-border effort.  
    
    Prior to joining CEC Capital, Ms. Hong was a Manager for Accenture’s (formerly Andersen Consulting) Strategic Services practice in San Francisco.   Before receiving her MBA, Ms. Hong worked as an engineer for Merck and worked on several plant start-ups, including a technology transfer project in China for a recombinant Hepatitis B vaccine, and for Merck’s launch of Crixivan, a protease inhibitor for HIV. 
    
    Ms. Hong has both her MBA and BS in Mechanical Engineering from UC Berkeley.
  • Gang Li

    Partner

    • Over 10 years experience in investment banking
    • Previously worked at IBD, CITIC Securities 
    • Master in Finance and Financial Management from Berlin School of Economics and Law
    
                                        
    Cancel
    Mr. Li once served as the Senior Vice President at CITIC Securities and participated in various projects covering refinancing, overseas M&A, asset restructuring and financial advising services. Since 2012, he has been focusing on the medical and healthcare industry. He has provided a full range of investment banking services for many distinguished companies such as Dianhong Pharmaceutical, Yiling Pharmaceutical, Yifeng Pharmacy, Shineway Pharmaceutical, Jointown Pharmaceutical and Huahai Pharmaceutical. During his tenure in CITIC Securities, he also directly promoted and participated in the establishment and implementation of several fund and asset management programs.
    
    Mr. Li holds a Master’s degree in International Finance and Finance Management from the Berlin School of Economics and Law, and is fluent in German and English.
  • Jin Li

    Partner

    • Over 15 years of experience in healthcare industry, investment and M&A.
    • Worked for GSK, Mindray, ASB Ventures, and BGI Co-win
    • Master of Biochemistry and Molecular Biology from Sun Yat-sen University, MBA from Peking University.
                                        
    Cancel
    Mr. Li Jin is a Partner at CEC Capital and Head of the Medtech Division. Since joining CEC Capital in 2020, Mr. Li has led the team to complete numerous financing transactions in Medtech, including notable deals such as WuXi Diagnostics, GenomePrecision Tech, b-ONE, NuProbe, Visionmedicals, and UnionStrong Tech. Before joining CEC Capital, he worked for BGI Co-win, focusing on private equity investments.
  • Bin Wang

    Managing Director

    • 10+ years of experience in the healthcare industry, including investment and investment banking
    • Previously worked at Beijing Jishuitan Hospital, VAMED, Concord Holdings, ZY Medical Investment, cn-healthcare.com, and Silver Mountain Capital
    • Holds a Bachelor's degree in Clinical Medicine from Shanghai Medical College, Fudan University, and an MBA from the University of Illinois at Chicago
                                        
    Cancel
    Mr. Bin Wang is currently serving as the Managing Director and Head of the Healthcare Services Team at CEC Capital. Since joining CEC Capital in 2018, Mr. Wang has demonstrated a profound understanding and extensive coverage of the healthcare services sector, leading the team to complete numerous financing transactions for companies such as Sanbo Brain Hospital, Tencent Doctor Work, Laoken Medical, Sunny Dental, Shanghai Donglei Brain Hospital, EverCare, Nubo Medical, Left Hand Doctor, Diagens. Prior to joining CEC Capital, he worked at Silver Mountain Capital, focusing on private equity investments.
  • Jieying Liao

    Managing Director

    • Years of experience in the Synthetic Biology industry and investment sector
    • Previously worked at NIH-NIEHS, Chinese Academy of Sciences (CAS), BGI Genomics, Hongtai Aplus, CAS VENTURE CAPITAL, and Cash Capital
    • Holds a Ph.D. in Biophysics from the Institute of Biophysics, Chinese Academy of Sciences
                                        
    Cancel
    Ms. Jieying Liao is currently serving as the Managing Director and Head of the Synthetic Biology Team at CEC Capital. She specializes in serving companies in the Synthetic Biology sector and related upstream and downstream industries. With a diverse background in research, industry, and investment, Ms. Liao has been instrumental in private equity investments in the healthcare industry at Cash Capital, representing projects such as Mabworks Biotech, Thousand Oaks Biologics, INNOGEN, RNACure, TIAN JIAN, Biocreatech and CASMN.
  • Ye Yuan

    Managing Director/ Head of GP&LP Investment and Exit

    • Over 10 years of experience in PE investment and management
    • Nearly 10 years of experience in Secondary Fund, with a cumulative fund management scale exceeding RMB 5 billion
    • Previously worked at Gopher Asset, Five Star Holdings Group, and China Renaissance as the head of Secondary Fund
    • Holds a EMBA in SAIF of SJTU; Bachelor of Statistics in SUFE
    
                                        
    Cancel
    Mr. Yuan Ye is currently serving as the Managing Director and the Head of GPLP Investment and Exit Services (S Fund Partner) at CEC Capital. Prior to this, he had previously worked at Gopher Asset, Five Star Holdings Group, and China Renaissance as the head of S Fund, and had earlier established the investment methodology and valuation system of S Fund in China. Mr. Yuan Ye is very familiar with the domestic GP&LP ecosystem. He has invested in more than 30 domestic GP’s fund shares, including Sequoia, Dachen, Matrix, StoneVC and etc. He has also led several complex Secondary deals, in forms of tender offering, portfolio transaction, structured financing and etc.
  • Zhang Xun

    Managing Director/ Head of Consumer

    • Over fifteen years of domestic and overseas investment banking experience, with in-depth coverage of the consumer industry
    • Familiar with domestic and overseas capital markets, led many A-share and Hong Kong private placements, IPOs, follow-ons, bond issuances and (cross-border) M&A projects
    • Previously worked in J.P. Morgan, China Renaissance Securities, CITIC Securities and Ping An Securities
    • Master of Finance from Shanghai Jiao Tong University; Bachelor of Finance from East China University of Science and Technology
                                        
    Cancel
    Mr. Zhang Xun is currently serving as the Managing Director and Head of Consumer team at CEC Capital. Before joining CEC Capital, he worked in the investment banking departments of J.P. Morgan, China Renaissance Securities, CITIC Securities and Ping An Securities, and has been deeply involved in the consumer industry investment banking business for more than ten years. Mr. Zhang Xun is very familiar with various products in domestic and overseas capital markets, and has been responsible for many private placements, IPOs, follow-ons, bond issuances and (cross-border) M&A projects for onshore/offshore listed/private clients.
  • Maggie Qi

    Head of ECM

    •Years of experience in capital markets and large enterprise groups
    •Worked for Zero2IPO Group and Aimer Group 
    •Master of Economics, Renmin University of China
                                        
    Cancel
    Ms. Maggie Qi is the head of the ECM of CEC Capital and has nearly ten years of investment bank experience in capital markets. Its team has the ability to cover more than 6,000 different types of investors at home and abroad, and provides in-depth services of "capital + industry" for customers in different fields of service, including equity financing, debt financing, industry landed in the local, and domestic and foreign business expansion. Ms. Maggie Qi has accumulated many years of in-depth coverage and cooperation experience in the fields of national background/government background investment institutions, listed companies, large enterprise groups, state enterprise and VC/PE. Led and finished:  4Paradigm、Sunwoda、BIRENTECH、SPICHE、汇付天下、AutoX、Lenovo and other leading enterprise.
  • China eCapital Partners LLC. (U.S.)

    For Team Information

    Please visit our official website
    www.ceccapitalus.com
                                        
    Cancel
    .